<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4558133</article-id><article-id pub-id-type="pmid">25909283</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Fibulin-5 inhibits Wnt/&#x003b2;-catenin signaling in lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Xiaojun</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Song</surname><given-names>Xiaomeng</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yue</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Dongshi</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yu</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="A3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Zhi</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lin</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Immunology, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Immuno Microenvironment and Disease of the Educational Ministry, Tianjin Medical University, Tianjin, P.R. China</aff><aff id="A2"><sup>2</sup> Department of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</aff><aff id="A3"><sup>3</sup> Department of Pathology, University of Pittsburgh Cancer Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Zhi Yao, <email>yaozhi@tijmu.edu.cn</email></corresp><corresp id="cor2">Lin Zhang, <email>zhanglx@upmc.edu</email></corresp></author-notes><pub-date pub-type="collection"><day>20</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>2</day><month>4</month><year>2015</year></pub-date><volume>6</volume><issue>17</issue><fpage>15022</fpage><lpage>15034</lpage><history><date date-type="received"><day>18</day><month>12</month><year>2014</year></date><date date-type="accepted"><day>14</day><month>3</month><year>2015</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2015 Chen et al.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Metastatic lung cancer is incurable and a leading cause of cancer death in the United States. However, the molecular mechanism by which lung cancer cells invade other tissues has remained unclear. We previously identified fibulin-5, an extracellular matrix protein, as a frequently silenced gene in lung cancer and a suppressor of cell invasion. In this study, we found fibulin-5 functions by inhibiting the Wnt/&#x003b2;-catenin pathway. The Cancer Genome Atlas (TCGA) datasets show a strong association between loss of fibulin-5 expression and poor outcomes of lung cancer patients, and also activation of the Wnt target genes <italic>MMP-7</italic> and <italic>c-Myc</italic>. Fibulin-5 impedes Wnt/&#x003b2;-catenin signaling by inhibiting extracellular signal-regulated kinase (ERK) to activate glycogen synthase kinase-3 &#x003b2; (GSK3&#x003b2;), which downregulates &#x003b2;-catenin and prevents its nuclear accumulation, leading to suppression of <italic>MMP-7</italic> and <italic>c-Myc</italic> expression. These effects of fibulin-5 are mediated by its amino-terminal integrin-binding RGD motif. Fibulin-5 also blocks Wnt/&#x003b2;-catenin signaling <italic>in vivo</italic> in H460 metastasis and H1299 tumor models. Furthermore, knockdown of <italic>&#x003b2;-catenin</italic> suppresses metastasis of H460 tumors, while knockdown of <italic>GSK3&#x003b2;</italic> promotes metastasis of fibulin-5-expressing H1752 tumors. Together, our results suggest that fibulin-5 functions as a metastasis suppressor in lung cancer by modulating tumor microenvironment to suppress Wnt/&#x003b2;-catenin signaling.</p></abstract><kwd-group><kwd>fibulin-5</kwd><kwd>lung cancer</kwd><kwd>invasion</kwd><kwd>MMP-7</kwd><kwd>&#x003b2;-catenin</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Lung cancer, accounting for nearly 27% of cancer deaths, is the leading cause of cancer death in the United States [<xref rid="R1" ref-type="bibr">1</xref>]. The high mortality rate of lung cancer is largely due to spread of disease to other organs [<xref rid="R2" ref-type="bibr">2</xref>]. Despite recent advances in early detection and targeted therapy, metastatic lung cancer remains incurable and results in poor patient outcomes. Understanding the molecular mechanism of lung cancer invasion and metastasis is crucial for developing novel and more effective therapeutic approaches.</p><p>The fibulin family, including fibulin-1&#x02013;7, is a group of widely expressed extracellular matrix (ECM) proteins involved in cell motility, cell adhesion, elastogenesis, as well as cell-to-cell and cell-to-matrix communication [<xref rid="R3" ref-type="bibr">3</xref>]. Aberrant expression of the fibulin family proteins has been described in a variety of tumors [<xref rid="R4" ref-type="bibr">4</xref>]. Depending on cell types and cellular contexts, fibulin family proteins can either suppress or promote tumor growth [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>]. Fibulin-5, a 66-KD secreted glycoprotein, is localized in elastic fibers and essential for proper elastic fiber assembly and vasculogenesis [<xref rid="R7" ref-type="bibr">7</xref>]. It has a unique feature of containing an Arg-Gly-Asp (RGD) motif, which can bind to cell-surface receptors known as integrins [<xref rid="R8" ref-type="bibr">8</xref>]. Integrins not only mediate cell adhesion to the ECM, but also regulate intracellular signaling through kinases such as extracellular signal-regulated kinase (ERK) and focal adhesion kinase (FAK) [<xref rid="R9" ref-type="bibr">9</xref>]. We previously identified <italic>fibulin-5</italic> and <italic>fibulin-3</italic> as two genes that are most frequently silenced by promoter hypermethylation in non-small cell lung cancer (NSCLC) [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R11" ref-type="bibr">11</xref>]. Fibulin-5 and fibulin-3 suppress lung cancer invasion and metastasis by inhibiting the expression of matrix metalloproteinase 7 (MMP-7) [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R12" ref-type="bibr">12</xref>], which promotes tumor metastasis by degrading the basement membrane that serves as a barrier to surrounding tissues [<xref rid="R13" ref-type="bibr">13</xref>]. However, it is unclear how fibulin-5 inhibits MMP-7 expression and lung cancer cell invasion.</p><p>The Wnt/&#x003b2;-catenin pathway plays a critical role in tumor initiation, progression and metastasis [<xref rid="R14" ref-type="bibr">14</xref>]. The central player &#x003b2;-catenin is an oncoprotein normally localized in the cytoplasm, where it forms a complex with several proteins, including the APC tumor suppressor and glycogen synthase kinase 3&#x003b2; (GSK3&#x003b2;) [<xref rid="R15" ref-type="bibr">15</xref>]. This complex promotes &#x003b2;-catenin phosphorylation by GSK3&#x003b2; and its subsequent poly-ubiquitination and proteasomal degradation [<xref rid="R15" ref-type="bibr">15</xref>]. Oncogenic mutations, such as inactivating <italic>APC</italic> mutations in colon cancer, result in the stabilization and translocation of &#x003b2;-catenin to the nucleus, where it binds to the T-cell factor (TCF) family of transcription factors to induce the expression of downstream target genes, such as <italic>c-Myc</italic>, <italic>CCND1</italic>, and <italic>MMP-7</italic>. The Wnt/&#x003b2;-catenin pathway is frequently activated in lung cancer [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>], and contributes to lung cancer cell proliferation, survival and metastasis [<xref rid="R17" ref-type="bibr">17</xref>&#x02013;<xref rid="R20" ref-type="bibr">20</xref>]. However, it is not fully understood how this pathway is aberrantly activated in lung cancer.</p><p>In this study, we found that loss of fibulin-5 expression in lung cancer is strongly associated with accumulation of &#x003b2;-catenin and activation of <italic>MMP-7</italic> and <italic>c-Myc</italic>. Fibulin-5, via its integrin-binding RGD motif, inhibits ERK to activate GSK3&#x003b2; and suppress &#x003b2;-catenin expression. Our results indicate that fibulin-5 functions as a metastasis suppressor in lung cancer by inhibiting Wnt/&#x003b2;-catenin signaling, and provide new insights on lung cancer invasion and metastasis.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Loss of fibulin-5 expression is correlated with poor outcomes of lung cancer patients</title><p><italic>Fibulin-5</italic> is known to be epigenetically silenced in lung cancer by promoter hypermethylation [<xref rid="R11" ref-type="bibr">11</xref>]. To further investigate its role in lung cancer, we analyzed the expression of <italic>fibulin-5</italic> in large datasets from The Cancer Genome Atlas (TCGA) databases. TCGA RNA Seq data showed marked downregulation of <italic>fibulin-5</italic> in over 50% of 1081 lung tumors analyzed, compared to normal control tissues, which all express high levels of <italic>fibulin-5</italic> (Fig. <xref ref-type="fig" rid="F1">1A</xref>). Expression of all 11 exons of <italic>fibulin-5</italic> is concomitantly reduced in lung tumors (Fig. <xref ref-type="fig" rid="F1">1B</xref>), suggesting altered regulation at its promoter. Consistent with our previous finding [<xref rid="R11" ref-type="bibr">11</xref>], hypermethylation in the genomic region of <italic>fibulin-5</italic> was detected by a probe in a substantial fraction of lung tumors (Fig. <xref ref-type="fig" rid="F1">1C</xref>). Importantly, loss of <italic>fibulin-5</italic> expression was found to be significantly associated with poor outcomes of lung cancer patients, including decreased overall survival (HR = 0.74; <italic>P</italic> = 9.7 &#x000d7; 10<sup>&#x02212;5</sup>) (Fig. <xref ref-type="fig" rid="F1">1D</xref>), earlier first progression (HR = 0.68; <italic>P</italic> = 3.3 &#x000d7; 10<sup>&#x02212;4</sup>) (Fig. <xref ref-type="fig" rid="F1">1E</xref>), and lower post-progression survival (HR = 0.75; <italic>P</italic> = 0.042) (<xref ref-type="supplementary-material" rid="SD1">Figure S1</xref>). These results, along with the association of fibulin-5 silencing and advanced tumors [<xref rid="R11" ref-type="bibr">11</xref>], strongly suggest that loss of <italic>fibulin-5</italic> expression plays an important role in lung cancer progression.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title><italic>Fibulin-5</italic> downregulation is correlated with poor prognosis of lung cancer</title><p><bold>A.</bold> Heatmap of <italic>fibulin-5</italic> mRNA expression in the TCGA lung cancer (LUNG) RNAseq (IlluminaHiSeq; <italic>N</italic> = 1081) dataset. <bold>B.</bold> Heatmap of <italic>fibulin-5</italic> exon expression in the TCGA lung cancer (LUNG) RNAseq (IlluminaHiSeq; <italic>N</italic> = 1081) dataset. <bold>C.</bold> Heatmap of <italic>fibulin-5</italic> methylation in the TCGA lung cancer (LUNG) HumanMethylation27 (Illumina 27K platform; <italic>N</italic> = 311) dataset. <bold>D.</bold> Kaplan-Meier curves for comparing overall survival (OS) of patients with lung tumors expressing high and low expression levels of <italic>fibulin-5</italic>. <bold>E.</bold> Kaplan-Meier curves for comparing first progression (FP) of patients with lung tumors expressing high and low levels of <italic>fibulin-5</italic>.</p></caption><graphic xlink:href="oncotarget-06-15022-g001"/></fig></sec><sec id="s2_2"><title><italic>Fibulin-5</italic> silencing is associated with elevated Wnt target genes and &#x003b2;-catenin in lung cancer</title><p>To understand how fibulin-5 suppresses lung cancer progression, we compared the expression of <italic>fibulin-5</italic> with other genes implicated in lung cancer progression. TCGA data showed an obvious inverse correlation between <italic>fibulin-5</italic> and <italic>MMP-7</italic> expression (Fig. <xref ref-type="fig" rid="F2">2A</xref>). A striking correlation between loss of fibulin-5 expression and induction of <italic>c-Myc</italic> was also noted; with most of the 1081 tumors analyzed expressing either low levels of <italic>fibulin-5</italic> but high levels of <italic>c-Myc</italic>, or high levels of <italic>fibulin-5</italic> but low levels of <italic>c-Myc</italic> (Fig. <xref ref-type="fig" rid="F2">2B</xref>).</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title><italic>Fibulin-5</italic> silencing is correlated with activation of the Wnt/&#x003b2;-catenin pathway in lung cancer</title><p><bold>A.</bold> Heatmap for comparing <italic>fibulin-5</italic> and <italic>MMP-7</italic> mRNA expression in the TCGA lung cancer (LUNG) RNAseq (IlluminaHiSeq; <italic>N</italic> = 1081) dataset. <bold>B.</bold> Heatmap for comparing <italic>fibulin-5</italic> and <italic>c-Myc</italic> mRNA expression in the TCGA lung cancer (LUNG) RNAseq (IlluminaHiSeq; <italic>N</italic> = 1081) dataset. <bold>C.</bold> Analysis of fibulin-5 and &#x003b2;-catenin expression in NSCLC by immunostaining. Pictures show an example tumor that is positive for fibulin-5 but negative for nuclear &#x003b2;-catenin staining, and an example tumor that is negative for fibulin-5 but positive for nuclear &#x003b2;-catenin staining. Arrows in the enlarged field indicate example cells with nuclear &#x003b2;-catenin staining. Scale bar: 50 &#x003bc;m. <bold>D.</bold> Summary of fibulin-5 and nuclear &#x003b2;-catenin staining results in 99 NSCLC samples. The inverse correlation between fibulin-5 expression and nuclear &#x003b2;-catenin expression was significant (<italic>P</italic> = 0.0073, two-tailed &#x003c7;2 test). <bold>E.</bold><italic>Top</italic>, summary of nuclear &#x003b2;-catenin expression and <italic>fibulin-5</italic> promoter methylation in an independent set of 30 pairs of lung tumors and matched pathologically normal lung tissues. <italic>Bottom</italic>, correlation of nuclear &#x003b2;-catenin expression and <italic>fibulin-5</italic> promoter methylation in lung tumors (<italic>P</italic> = 0.0235, two-tailed &#x003c7;2 test).</p></caption><graphic xlink:href="oncotarget-06-15022-g002"/></fig><p>Since both <italic>MMP-7</italic> and <italic>c-Myc</italic> are downstream effectors of the Wnt/&#x003b2;-catenin pathway [<xref rid="R21" ref-type="bibr">21</xref>], we hypothesized that the function of fibulin-5 in lung cancer is mediated through Wnt/&#x003b2;-catenin signaling. Upon analyzing an NSCLC tissue microarray by immunostaining (Fig. <xref ref-type="fig" rid="F2">2C</xref> and <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>), we detected a statistically significant (<italic>P</italic> = 0.0073) association between loss of fibulin-5 expression and accumulation of nuclear &#x003b2;-catenin. While 64.6% (64/99) of tumors expressed either fibulin-5 or nuclear &#x003b2;-catenin, only 14.1% (14/99) were positive for both (Fig. <xref ref-type="fig" rid="F2">2D</xref>). Further analysis of an independent set of 30 matched tumor and normal pairs showed a significant (<italic>P</italic> = 0.0235) association of <italic>fibulin-5</italic> promoter methylation and &#x003b2;-catenin expression, with 76.9% (10/13) of tumors having <italic>fibulin-5</italic> promoter methylation and nuclear &#x003b2;-catenin staining, compared to 35.3% (6/17) lacking <italic>fibulin-5</italic> promoter methylation but expressing nuclear &#x003b2;-catenin (Fig. <xref ref-type="fig" rid="F2">2E</xref>). These results suggest that loss of fibulin-5 expression contributes to activation of the Wnt pathway components, including &#x003b2;-catenin, c-Myc, and MMP-7, in lung cancer.</p></sec><sec id="s2_3"><title>Fibulin-5 suppresses &#x003b2;-catenin nuclear localization and TCF4 activity in lung cancer cells</title><p>The functional role of fibulin-5 in suppression of lung cancer was investigated. Transfection of <italic>fibulin-5</italic> into fibulin-5-negative NSCLC cells, including A549, H1299 and H460 cells, inhibited colonogenic formation (<xref ref-type="supplementary-material" rid="SD1">Fig. S2A</xref>). Stable expression of fibulin-5 in A549 and H1299 cells suppressed cell invasion [<xref rid="R11" ref-type="bibr">11</xref>], as well as cell proliferation determined by MTT assay (<xref ref-type="supplementary-material" rid="SD1">Fig. S2, B and C</xref>). Nonetheless, fibulin-5 expression did not induce substantial apoptosis in lung cancer cells (data not shown).</p><p>We determined whether the effects of fibulin-5 on lung cancer invasion and MMP-7 expression are mediated by Wnt/&#x003b2;-catenin signaling, which is known to regulate MMP-7 expression in colorectal cancer cells [<xref rid="R21" ref-type="bibr">21</xref>]. Fibulin-5 expression substantially decreased the level of nuclear &#x003b2;-catenin in A549 and H1299 cells (Fig. <xref ref-type="fig" rid="F3">3A</xref>), and in SW480 colorectal cancer cells, which express abundant nuclear &#x003b2;-catenin (<xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>). Knockdown of <italic>fibulin-5</italic> by siRNA in H1752 lung cancer cells, which express endogenous fibulin-5, was sufficient to induce the expression of nuclear &#x003b2;-catenin (Fig. <xref ref-type="fig" rid="F3">3B</xref>), and also promote cell invasion [<xref rid="R11" ref-type="bibr">11</xref>]. Furthermore, transfection of <italic>fibulin-5</italic> into A549 and H1299 cells, but not the control vector, inhibited the activity of the TOPFlash (OT) TCF-4 reporter, without affecting the control FOPFlash (OF) reporter (Fig. <xref ref-type="fig" rid="F3">3C</xref>). Fibulin-5 also inhibited transactivation of the TOPFlash reporter by wild-type (WT) &#x003b2;-catenin, and that by a tumor-derived mutant &#x003b2;-catenin lacking the amino-terminal phosphorylation sites (&#x00394;N) required for its degradation (Fig. <xref ref-type="fig" rid="F3">3D</xref>). These results suggest that fibulin-5 inhibits the Wnt pathway by preventing &#x003b2;-catenin accumulation and nuclear translocation.</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Fibulin-5 inhibits &#x003b2;-catenin nuclear translocation and TCF-4 activity</title><p><bold>A.</bold> Western blotting of &#x003b2;-catenin in nuclear fractions isolated from H1299 and A549 cells at 24 hr after transfection with <italic>fibulin-5</italic> or the control empty vector. <bold>B.</bold> H1752 cells transfected with <italic>fibulin-5</italic> or control siRNA were analyzed for &#x003b2;-catenin by immunostaining 48 hr after transfection. <italic>Left</italic>, representative pictures of &#x003b2;-catenin immunostaining. Scale bar, 5 &#x003bc;m. <italic>Right</italic>, quantification of cells with nuclear &#x003b2;-catenin (<italic>P</italic> = 0.0002, Student's <italic>t</italic> test). <bold>C.</bold> A549 and H1299 cells were transfected with <italic>fibulin-5</italic> along with the TCF-4 reporter pTOPFlash (OT) or the control inactive reporter pFOPFlash (OF). Normalized luciferase activities were determined 24 hr after transfection. The activity of the OF was defined as 1.0. <bold>D.</bold> The effects of fibulin-5 on TCF-4 reporter activities induced by WT or mutant &#x003b2;-catenin (&#x00394;N). &#x00394;N: the mutant &#x003b2;-catenin with amino-terminal 45 amino acids deleted. Reporter assays were performed as in (C).</p></caption><graphic xlink:href="oncotarget-06-15022-g003"/></fig></sec><sec id="s2_4"><title>Fibulin-5 inhibits the Wnt/&#x003b2;-catenin pathway to suppress lung cancer cell invasion and MMP-7 expression</title><p>We further examined whether and how fibulin-5 regulates the Wnt/&#x003b2;-catenin pathway to suppress lung cancer invasion. Fibulin-5 transfection markedly decreased the protein and mRNA expression of <italic>c-Myc</italic> and <italic>CCND1</italic>, two major TCF-4 downstream targets [<xref rid="R22" ref-type="bibr">22</xref>, <xref rid="R23" ref-type="bibr">23</xref>] (Fig. <xref ref-type="fig" rid="F4">4A and 4B</xref>). Conversely, knockdown of <italic>fibulin-5</italic> by siRNA in H1752 cells stimulated the expression of &#x003b2;-catenin, c-Myc, cyclin D1 and MMP-7 (Fig. <xref ref-type="fig" rid="F4">4C</xref>). Similar to <italic>fibulin-5</italic> transfection (Fig. <xref ref-type="fig" rid="F4">4A</xref>) [<xref rid="R11" ref-type="bibr">11</xref>], knockdown of <italic>&#x003b2;-catenin</italic> by siRNA in A549 and H1299 cells suppressed the expression of c-Myc, cyclin D1 and MMP-7 (Fig. <xref ref-type="fig" rid="F4">4D</xref>), as well as cell invasion determined by the Matrigel invasion assay (Fig. <xref ref-type="fig" rid="F4">4E</xref> and <xref ref-type="supplementary-material" rid="SD1">S4A</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Fibulin-5 suppresses Wnt target gene expression by inhibiting ERK and GSK3&#x003b2; phosphorylation</title><p><bold>A.</bold> Western blot analysis of the indicated proteins in H1299 and A549 cells 24 hr after transfection with <italic>fibulin-5</italic> or the control empty vector. <bold>B.</bold> Real-time RT-PCR analysis of <italic>c-Myc</italic> and <italic>CCND1</italic> mRNA expression in H1299 and A549 cells at indicated time points after <italic>fibulin-</italic>5 transfection. <italic>Glyceraldehyde-3-phosphate dehydrogenase</italic> (<italic>GAPDH</italic>), a house-keeping gene, was used as an internal control. The results were normalized to the cells without <italic>fibulin-5</italic> transfection (0 hr), which were defined as 1.0. <bold>C.</bold> Western blot analysis of the indicated proteins in H1752 cells at 48 hr after transfection with control or <italic>fibulin-5</italic> siRNA. <bold>D.</bold> Western blot analysis of the indicated proteins in A549 and H1299 cells 36 hr after transfection with control or <italic>&#x003b2;-catenin</italic> siRNA. <bold>E.</bold> Matrigel invasion analysis of A549 and H1299 cells transfected with control or <italic>&#x003b2;-catenin</italic> siRNA as in (D). The results are the average of three independent experiments (<italic>P</italic> = 0.0001 for both si control and si <italic>&#x003b2;-catenin</italic>, Students' <italic>t</italic> test). <bold>F.</bold> Western blot analysis of the indicated proteins in stable fibulin-5-expressing A549 cells (A549-fibulin-5) 24 hr after transfection with control or <italic>GSK3&#x003b2;</italic> siRNA. <bold>G.</bold> Matrigel invasion analysis of the parental and stable fibulin-5-expressing A549 cells with or without <italic>GSK3&#x003b2;</italic> knockdown as in (F) (si control, <italic>P</italic> = 0.0001; si <italic>GSK3&#x003b2;, P</italic> = <italic>0.1264</italic>, Student's <italic>t</italic> test). <bold>H.</bold> Western blot analysis of the indicated proteins in A549 cells and H1299 cells treated with 50 &#x003bc;M of the ERK inhibitor PD98059 for the indicated time. <bold>I.</bold> Western blot analysis of the indicated proteins in A549 cells and H1299 cells 24 hr after transfection with wild-type (WT) <italic>ERK</italic>, dominant negative (DN) <italic>ERK</italic>, or the control empty vector.</p></caption><graphic xlink:href="oncotarget-06-15022-g004"/></fig><p>&#x003b2;-catenin level is primarily regulated by ubiquitin/proteasome-mediated protein degradation, following its phosphorylation by GSK3&#x003b2; [<xref rid="R15" ref-type="bibr">15</xref>], whose kinase activity is governed by the inhibitory Ser9 phosphorylation [<xref rid="R24" ref-type="bibr">24</xref>]. Ser9 phosphorylation of GSK3&#x003b2; was markedly reduced following fibulin-5 transfection in A549 and H1299 cells (Fig. <xref ref-type="fig" rid="F4">4A</xref>), while increased in fibulin-5-depleted H1752 cells (Fig. <xref ref-type="fig" rid="F4">4C</xref>), but barely changed upon &#x003b2;-catenin depletion (Fig. <xref ref-type="fig" rid="F4">4D</xref>). Knockdown of <italic>GSK3&#x003b2;</italic> by siRNA in the stable fibulin-5-expressing A549 cells restored expression of &#x003b2;-catenin, c-Myc, cyclin D1 and MMP-7 (Fig. <xref ref-type="fig" rid="F4">4F</xref>), and invasive capacity (Fig. <xref ref-type="fig" rid="F4">4G</xref> and <xref ref-type="supplementary-material" rid="SD1">S4B</xref>).</p><p>The effect of fibulin-5 on invasion is mediated by inhibition of ERK kinase [<xref rid="R11" ref-type="bibr">11</xref>], which promotes Ser9 phosphorylation of GSK3&#x003b2; [<xref rid="R24" ref-type="bibr">24</xref>]. Similar to fibulin-5 transfection, the ERK inhibitor PD98059 suppressed GSK3&#x003b2; Ser9 phosphorylation and c-Myc expression in both A549 and H1299 cells (Fig. <xref ref-type="fig" rid="F4">4H</xref>). Transfecting A549 and H1299 cells with dominant negative (DN) ERK, but not wild-type ERK, also inhibited GSK3&#x003b2; phosphorylation and c-Myc expression (Fig. <xref ref-type="fig" rid="F4">4I</xref>). Together, these results indicate that fibulin-5 suppresses MMP-7 expression and lung cancer invasion through ERK inhibition and GSK3&#x003b2; activation, which in turn prevents &#x003b2;-catenin accumulation and nuclear translocation.</p></sec><sec id="s2_5"><title>Fibulin-5 downregulates MMP-7 through its integrin-binding RGD motif</title><p>There are at least two TCF-4 binding elements (TBEs) in the promoter region of <italic>MMP-7</italic> [<xref rid="R12" ref-type="bibr">12</xref>]. <italic>Fibulin-5</italic> transfection markedly inhibited activity of an <italic>MMP-7</italic> reporter construct containing these TBEs in A549 and H1299 cells, but not that of a reporter containing point mutations in both TBEs (Fig. <xref ref-type="fig" rid="F5">5A</xref>), suggesting the inhibitory effect of fibulin-5 on <italic>MMP-7</italic> is mediated at the transcriptional level through the TBEs.</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Fibulin-5 suppresses MMP-7 expression through its integrin-binding RGD motif</title><p><bold>A.</bold>
<italic>Upper</italic>, schematic representation of <italic>MMP-7</italic> promoter region containing two TCF4 binding elements (TBEs). Asterisks indicate the mutated nucleotides. <italic>Lower</italic>, A549 and H1299 cells were transfected with the control (pBV-Luc) or <italic>MMP-7</italic> reporter, along with <italic>fibulin-5</italic> or the empty pCDNA vector. Luciferase activities were measured 24 hr after transfection and normalized to that of the &#x003b2;-galactosidase reporter. <bold>B.</bold> A549 and H1299 cells were transfected with the control (pBV-Luc) or <italic>MMP-7</italic> reporter, along with WT <italic>fibulin-5</italic>, <italic>fibulin-5</italic> with the RGD domain deletion (&#x00394;RGD), or the empty pCDNA vector. Luciferase activities were measured as in (A). <bold>C.</bold> Western blotting of the indicated proteins in A549 and H1299 cells 24 hr after transfection with WT or &#x00394;RGD <italic>fibulin-5</italic>. <bold>D.</bold> A549 and H1299 cells were co-transfected with V5-tagged fibulin-5, along with Flag-tagged &#x003b1;v or Myc-tagged &#x003b2;3. IP was performed with anti-Flag or anti-Myc antibody, followed by western blotting of the indicated proteins. <bold>E.</bold> IP was performed on A549 and H1299 cells co-transfected with V5-tagged &#x00394;RGD along with Flag-tagged &#x003b1;v or Myc-tagged &#x003b2;3.</p></caption><graphic xlink:href="oncotarget-06-15022-g005"/></fig><p>Fibulin-5 is distinguished from other fibulin family members in its unique RGD motif. Inhibition of the Wnt pathway by fibulin-5 requires the RGD motif, as the mutant fibulin-5 lacking the RGD motif (&#x00394;RGD) was unable to suppress the <italic>MMP-7</italic> reporter (Fig. <xref ref-type="fig" rid="F5">5B</xref>), GSK3&#x003b2; Ser9 phosphorylation, or c-Myc and cyclin D1 expression in A549 and H1299 cells (Fig. <xref ref-type="fig" rid="F5">5C</xref>). We then used IP to probe potential interactions between fibulin-5 and integrins, which can bind to RGD-containing proteins [<xref rid="R9" ref-type="bibr">9</xref>]. While WT fibulin-5 could bind to the integrin subunits &#x003b1;v and &#x003b2;3 in A549 and H1299 cells (Fig. <xref ref-type="fig" rid="F5">5D</xref>), &#x00394;RGD could not interact with either subunit (Fig. <xref ref-type="fig" rid="F5">5E</xref>). Therefore, the inhibitory effect of fibulin-5 on the Wnt pathway in lung cancer is mediated by the integrin-binding RGD motif.</p></sec><sec id="s2_6"><title>Fibulin-5 suppresses tumor growth and metastasis and Wnt/&#x003b2;-catenin signaling <italic>in vivo</italic></title><p>Xenograft tumor models were used to further determine the role of fibulin-5 in suppressing lung tumor growth <italic>in vivo</italic>. Fibulin-5 expression significantly (<italic>P</italic> = 0.0007) suppressed the growth of H1299 xenograft tumors in nude mice (Fig. <xref ref-type="fig" rid="F6">6A and 6B</xref>). In line with reduced tumor growth, expression of p-ERK, nuclear &#x003b2;-catenin, c-Myc and MMP-7 was found to be substantially decreased in fibulin-5-expressing H1299 tumors, compared to the parental H1299 tumors lacking fibulin-5 expression (Fig. <xref ref-type="fig" rid="F6">6C</xref>). Because A549 and H1299 cells do not form lung metastasis, we used H460 and H1752 cells to analyze the effect of fibulin-5 on tumor metastasis. We found that lung metastasis, established from fibulin-5-expressing H460 cells by intravenous injection [<xref rid="R11" ref-type="bibr">11</xref>], also expressed much lower levels of p-ERK, nuclear &#x003b2;-catenin, c-Myc and MMP-7, relative to the parental H460 tumors (Fig. <xref ref-type="fig" rid="F7">7A</xref>). Knockdown of <italic>&#x003b2;-catenin</italic> in H460 cells by using lenti-viral shRNA significantly suppressed lung metastasis of H460 tumors (Fig. <xref ref-type="fig" rid="F7">7B&#x02013;D</xref>). Furthermore, knockdown of <italic>GSK3&#x003b2;</italic> in H1752 cells by shRNA was sufficient to promote lung metastasis of H1752 tumors (Fig. <xref ref-type="fig" rid="F7">7E&#x02013;G</xref>). These findings indicate that fibulin-5 functions as a suppressor of lung tumor growth and metastasis <italic>in vivo</italic> by inhibiting the Wnt/&#x003b2;-catenin pathway.</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Fibulin-5 inhibits lung tumor progression and the Wnt pathway in mice</title><p><bold>A.</bold> Parental and fibulin-5-expressing H1299 cells were injected subcutaneously into BALB/c nude mice to establish xenograft tumors. Tumor volumes at indicated time points after inoculation were calculated and plotted (<italic>n</italic> = 5 in each group). The difference between parental and fibulin-5-expressing tumors was statistically significant (<italic>P</italic> = 0.0007, Fisher's exact test). <bold>B.</bold> Representative pictures of tumors at the end of experiments. <bold>C.</bold> Immunostaining analysis of V5 (fibulin-5), p-ERK, &#x003b2;-catenin, c-Myc, and MMP-7 in tumor tissues from (B). Scale bar, 20 &#x003bc;m.</p></caption><graphic xlink:href="oncotarget-06-15022-g006"/></fig><fig id="F7" orientation="portrait" position="float"><label>Figure 7</label><caption><title>The Wnt pathway can be inhibited by fibulin-5 in metastatic tumors in mice and is critical for tumor metastasis</title><p><bold>A.</bold> Representative immunostaining pictures of p-ERK, &#x003b2;-catenin, c-Myc, and MMP-7 in the parental and fibulin-5-expressing H460 xenograft tumors. Scale bar, 20 &#x003bc;m. <bold>B.</bold> Western blot analysis of &#x003b2;-catenin in H460 cells expressing <italic>&#x003b2;-catenin</italic> or control shRNA. <bold>C.</bold> H460 cells expressing <italic>&#x003b2;-catenin</italic> or control shRNA were injected (10<sup>6</sup> cells/injection) i.v. by tail vein into BALB/c nude mice. Representative pictures of fixed lungs at 6 weeks after injection were shown (Scale bar, 0.5 cm), along with H&#x00026;E staining pictures (Scale bar, 50 &#x003bc;m). <bold>D.</bold> Quantification of metastasis nodules in H460 tumors in (C). The difference between the two groups was statistically significant (<italic>P</italic> = 0.0026, Student's <italic>t</italic> test). <bold>E.</bold> Western blot analysis of GSK3&#x003b2; in H1752 cells expressing <italic>GSK3&#x003b2;</italic> or control shRNA. <bold>F.</bold> H1752 cells expressing <italic>&#x003b2;-catenin</italic> or control shRNA were injected (10<sup>6</sup> cells/injection) i.v. by tail vein into BALB/c nude mice. Representative pictures of fixed lungs at 6 weeks after injection were shown (Scale bar, 0.5 cm), along with H&#x00026;E staining pictures (Scale bar, 50 &#x003bc;m). <bold>G.</bold> Quantification of metastasis nodules in H1752 tumors in (F). The difference between the two groups was statistically significant (<italic>P</italic> = 0.0028, Student's <italic>t</italic> test). <bold>H.</bold> A model of fibulin-5-mediated suppression of lung cancer cell invasion and proliferation.</p></caption><graphic xlink:href="oncotarget-06-15022-g007"/></fig></sec></sec><sec id="s3"><title>DISCUSSION</title><p>Fibulin-5 is frequently downregulated in more than 50% of lung cancer at least in part due to promoter hypermethylation (Fig. <xref ref-type="fig" rid="F1">1A&#x02013;C</xref>) [<xref rid="R11" ref-type="bibr">11</xref>]. Loss of fibulin-5 expression is associated with poor survival of lung cancer patients and disease progression (Fig. <xref ref-type="fig" rid="F1">1D</xref> and <xref ref-type="supplementary-material" rid="SD1">S1</xref>). The anti-tumor effect of fibulin-5 is mediated through tumor microenvironment and suppression of MMP-7, which is overexpressed in NSCLC and associated with poor prognosis [<xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>]. In addition to MMP-7, fibulin-5 can also regulate other metalloproteinases. It inhibits MMP-2, MMP-3, TIMP-1, and TIMP-3 in preventing tumor angiogenesis [<xref rid="R31" ref-type="bibr">31</xref>], and MMP-9 through an autocrine loop in blocking lung and liver metastasis mediated by stromal fibroblasts [<xref rid="R32" ref-type="bibr">32</xref>]. However, several studies showed tumor-promoting activity of fibulin-5 [<xref rid="R33" ref-type="bibr">33</xref>, <xref rid="R34" ref-type="bibr">34</xref>], suggesting cell type- and context-dependent functions of fibulin-5 in cancer. The prominent role of fibulin-5 in lung cancer is in line with its function in pulmonary physiology and pathology. For example, altered fibulin-5 expression has been linked to lung injury and pulmonary hypertension [<xref rid="R35" ref-type="bibr">35</xref>, <xref rid="R36" ref-type="bibr">36</xref>]. Fibulin-5-deficient mice primarily exhibited pulmonary phenotypes such as lung emphysemas, a risk factor of lung cancer [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R37" ref-type="bibr">37</xref>].</p><p>Wnt/&#x003b2;-catenin signaling has recently emerged as a critical player in lung cancer [<xref rid="R38" ref-type="bibr">38</xref>]. Some lung cancer cells express high levels of nuclear &#x003b2;-catenin, resulting in induction of Wnt target genes and enhanced cell proliferation [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>]. Our results indicate that fibulin-5 functions as an inhibitor of Wnt/&#x003b2;-catenin signaling in lung cancer, as indicated by the strong association of loss of fibulin-5 expression and accumulation of &#x003b2;-catenin, MMP-7 and c-Myc in lung tumors (Fig. <xref ref-type="fig" rid="F2">2</xref>), and suppression of the Wnt pathway components by fibulin-5 in NSCLC cells (Figs. <xref ref-type="fig" rid="F3">3</xref>&#x02013;<xref ref-type="fig" rid="F5">5</xref>). Fibulin-5 does not seem to be directly involved in &#x003b2;-catenin degradation, as it inhibits both WT and mutant &#x003b2;-catenin lacking the phosphorylation sites required for its degradation (Fig. <xref ref-type="fig" rid="F3">3D</xref>). It may facilitate retaining of &#x003b2;-catenin in the cytoplasm, where it binds to several other proteins that promote its subsequent turnover. In addition to fibulin-5 silencing, several other aberrations in lung cancer can lead to activation of the Wnt pathway, such as overexpression of Wnt ligands [<xref rid="R20" ref-type="bibr">20</xref>], downregulation of Wnt antagonists such as dickkopf 3 [<xref rid="R10" ref-type="bibr">10</xref>], and loss of fibulin-3 expression [<xref rid="R12" ref-type="bibr">12</xref>]. Since lung cancer cells generally lack <italic>APC</italic> and <italic>&#x003b2;-catenin</italic> mutations that are frequently found in colon tumors, they probably have to rely on multiple changes in the Wnt pathway regulators, which may complement each other in sustaining high levels of Wnt signaling.</p><p>Although c-Myc is frequently overexpressed, the amplification <italic>c-Myc</italic> genomic region was rare in NSCLC [<xref rid="R39" ref-type="bibr">39</xref>]. Our results suggest that fibulin-5 silencing contributes to c-Myc overexpression in lung cancer. Suppression of lung cancer metastasis by fibulin-5 may be mediated in part through c-Myc, which can promote lung cancer metastasis in mice [<xref rid="R40" ref-type="bibr">40</xref>]. Fibulin-5 may also be involved in regulating Wnt signaling in response to lung injury, in which Wnt signaling and MMP-7 were found to be concomitantly regulated [<xref rid="R41" ref-type="bibr">41</xref>].</p><p>Our results suggest that fibulin-5 antagonizes Wnt signaling by inhibiting ERK and indirectly activating GSK3&#x003b2; to restrain &#x003b2;-catenin in the cytoplasm, which prevents MMP-7 and c-Myc expression and lung cancer cell invasion and proliferation (Fig. <xref ref-type="fig" rid="F7">7H</xref>). The effect of fibulin-5 is likely to be mediated by its binding to cell-surface integrins, as it requires the RGD motif that binds to &#x003b1;v&#x003b2;3 in lung cancer cells (Fig. <xref ref-type="fig" rid="F5">5B&#x02013;E</xref>). Integrin-mediated signaling is known to be involved in cell migration and invasion, as well as activation of MMPs and TIMPs [<xref rid="R42" ref-type="bibr">42</xref>]. Fibulin-5 has been shown to bind to the integrins &#x003b1;v&#x003b2;3, &#x003b1;v&#x003b2;5, and &#x003b1;9&#x003b2;1 to promote endothelial cell adhesion [<xref rid="R8" ref-type="bibr">8</xref>]. It is possible that the effect of fibulin-5 in lung cancer involves integrins other than &#x003b1;v&#x003b2;3, which will be investigated in our future studies. The RGD motif of fibulin-5 may also be useful for developing peptide mimetic or small molecule inhibitors for targeting metastatic lung cancer. Activation of the Wnt pathway due to fibulin-5 silencing may help drive epithelial-mesenchymal transition (EMT), a critical event in cancer metastasis, which is known to involve aberrant Wnt signaling, ERK signaling, and MMP activation [<xref rid="R43" ref-type="bibr">43</xref>]. Fibulin-5 was found to regulate EMT as a target of transforming growth factor &#x003b2; (TGF&#x003b2;) [<xref rid="R34" ref-type="bibr">34</xref>]. These observations made by us and other groups will likely stimulate further interest in delineating how fibulin-5 silencing drives EMT-related events during lung cancer invasion and metastasis.</p><p>Collectively, our results demonstrate an important functional role of fibulin-5 in suppressing Wnt/&#x003b2;-catenin signaling and lung cancer invasion. Further investigation of the functional role of fibulin-5 may provide useful information for developing biological or pharmacological agents for targeting metastatic lung cancer.</p></sec><sec sec-type="materials|methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Bioinformatics analysis</title><p><italic>Fibulin-5</italic>, <italic>MMP-7</italic> and <italic>c-Myc</italic> expression and <italic>fibulin-5</italic> DNA methylation in The Cancer Genome Atlas (TCGA) databases were analyzed by using The UCSC Cancer Genomics Browser (<ext-link ext-link-type="uri" xlink:href="https://genome-cancer.soe.ucsc.edu/proj/site/hgHeatmap/">https://genome-cancer.soe.ucsc.edu/proj/site/hgHeatmap/</ext-link>) [<xref rid="R25" ref-type="bibr">25</xref>]. The TCGA lung cancer (LUNG) RNAseq (IlluminaHiSeq; <italic>N</italic> = 1081) and DNA methylation (HumanMethylation27; Illumina 27K platform; <italic>N</italic> = 311) datasets were used to compare <italic>fibulin-5</italic>, <italic>MMP-7</italic> and <italic>c-Myc</italic> expression and <italic>fibulin-5</italic> DNA methylation, because these datasets include results from control normal tissues. Heatmap mode was used to display the results. Kaplan-Meier curves were generated using the Kaplan-Meier plotter program (<ext-link ext-link-type="uri" xlink:href="http://kmplot.com/analysis/">http://kmplot.com/analysis/</ext-link>) as described [<xref rid="R26" ref-type="bibr">26</xref>].</p></sec><sec id="s4_2"><title>Tissue samples and immunostaining</title><p>Tissue microarray slides containing 99 NSCLC samples were purchased from US Biomax (Rockville, MD). The information of these samples was summarized in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>. An independent set of frozen specimens with known <italic>fibulin-5</italic> promoter methylation status, including 30 randomly selected lung tumors and the matched histologically normal lung parenchyma samples, were previously described [<xref rid="R11" ref-type="bibr">11</xref>]. Fibulin-5 and &#x003b2;-catenin immunostaining was performed as described [<xref rid="R10" ref-type="bibr">10</xref>]. The staining distribution was scored based on the percentage of positive cells: 0, 0%; 1, 1&#x02013;30%; 2, 31&#x02013;60%; 3, 61&#x02013;100%. The criteria used for scoring signal intensity were: 0, no signal; 1, weak; 2, moderate; and 3, marked. The staining was considered to be positive if the sum of distribution and intensity scores was &#x0003e; 2.</p></sec><sec id="s4_3"><title>Cell culture and transfection</title><p>Lung cancer cell lines were obtained from American Type Culture Collection (Manassas, VA). Cells were maintained at 37&#x000b0;C and 5% CO<sub>2</sub>, and cultured in RPMI 1640 medium (Mediatech, Herndon, VA) supplemented with 10% defined fetal bovine serum (HyClone, Logan, UT), 100 U/ml penicillin and 100 &#x003bc;g/ml streptomycin (Invitrogen, Carlsbad, CA). Transfection of plasmids and small interfering RNA (siRNA) was performed using Lipofectamine&#x02122; 2000 (Invitrogen) as described [<xref rid="R27" ref-type="bibr">27</xref>]. Expression vectors including wild-type ERK (plasmid #49328) and dominant negative (DN) ERK (K71R; plasmid #49329) were obtained from Addgene (Cambridge, MA). Fibulin-5 was knocked down by ON-TARGET plus siRNA J-017621-05 (ThermoFisher, Waltham, MA). <italic>&#x003b2;-catenin</italic> and <italic>GSK3&#x003b2;</italic> in A549 and H1299 cells were knocked down using pre-made siRNA (Santa Cruz Biotechnology, Santa Cruz, CA). <italic>&#x003b2;-catenin</italic> and <italic>GSK3&#x003b2;</italic> in H460 and H1752 cells were stably knocked down by transduction with pre-made lenti-viral short hairpin RNA (shRNA) vectors (Shanghai Genechem, Shanghai, China) as previously described [<xref rid="R28" ref-type="bibr">28</xref>]. The shRNA vectors included shRNA #18745 for <italic>&#x003b2;-catenin</italic> (target sequence: 5&#x02032;-TTGGAATGAGACTGCTGAT-3&#x02032;) and shRNA #9374 for <italic>GSK3&#x003b2;</italic> (target sequence: 5&#x02032;-ACTGATTATACCTCTAGTA-3&#x02032;). The infected cells were selected by puromycin at 5 &#x003bc;g/mL for H460 cells, and 3 &#x003bc;g/mL for H1752 cells. Cell viability was analyzed for cells seeded at 2 &#x000d7; 10<sup>3</sup>/well in 96-well plates using MTT assay kit (Promega, Madison, WI) according to the manufacturer's instructions.</p></sec><sec id="s4_4"><title>Western blots and immunoprecipitation</title><p>Collection of cell lysates and western blotting were done as previously described (24). The antibodies used for western blotting included those for p-GSK3&#x003b2; (Ser9), ERK, p-ERK (Thr202/Tyr204) (Cell Signaling Technology, Danvers, MA), cyclin D, c-Myc (9E10) (Santa Cruz Biotechnology), MMP7 (EMD Millipore, Billerica, MA), V5 (Invitrogen), &#x003b2;-actin (Sigma, St. Louis, MO), and &#x003b2;-catenin (BD Biosciences, San Jose, CA).</p><p>For immunoprecipitation (IP), cells were harvested by centrifugation and washed once with PBS on ice. Cells were lysed for 15 min with RIPA buffer (150 mM NaCl, 50 mM Tris, 1% NP-40, and 0.5% deoxycholate) containing 1:100 protease/phosphatase inhibitors (Sigma). After vortexing, the lysates were cleared by centrifugation, and then frozen at &#x02212;80&#x000b0;C or used immediately for IP. For each IP reaction, lysate containing 500&#x02013;600 mg proteins was used. Briefly, cell lysates were incubated with 2 mg of anti-FLAG (Sigma) or anti-Myc (9E10; Santa Cruz Biotechnology) at 4&#x000b0;C overnight, and then incubated with protein-G sepharose (Life technologies, Grand Island, NY) at room temperature for 2 hr with rocking. After centrifugation, the beads were washed once with 500 &#x003bc;L RIPA buffer containing protease/phosphatase inhibitors, 3 times with 1 mL of RIPA buffer, and then boiled in 2&#x000d7; Laemmli sample buffer. Whole cell lysates prepared before IP were used as a control for input. Samples were run on an SDS-PAGE pre-cast gels at 100 V for 1 hr (Bio-Rad, Hercules, CA), blotted onto Immobilon-P PVDF membranes (EMD Millipore), and then blocked with either 5% non-fat dry milk or 5% BSA diluted in wash buffer (0.1% tween-20 in TBS). After incubation with primary and secondary antibodies at 4&#x000b0;C, blots were developed using the ECL chemiluminescent detection kit (Amersham Biosciences, Buckinghamshire, UK).</p></sec><sec id="s4_5"><title>Reverse transcriptase (RT)-polymerase chain reaction (PCR)</title><p>Total RNA was isolated from lung cancer cells using the RNAgents Total RNA Isolation System (Promega). First-strand cDNA was synthesized from 10 &#x003bc;g of total RNA using Superscript II reverse transcriptase (Invitrogen). The PCR primers include those for <italic>CCND1</italic>, 5&#x02032;-CCCTCGGTGTCCTACTTCAAA-3&#x02032;/5&#x02032; CCAGGTTCCACTTGAGCTTGT-3&#x02032; and <italic>c-Myc</italic>, 5&#x02032;-CCTCAACGTTAGCTTCACCAA-3&#x02032;/5&#x02032;-TTTGATGAA GGTCTCGTCGTC-3&#x02032;. PCR reactions were performed on an MJ Mini Personal thermo cycler (Bio-Rad) with <italic>glyceraldehyde-3-phosphate dehydrogenase</italic> (<italic>GAPDH</italic>) as the internal control. The cycle conditions are available upon request.</p></sec><sec id="s4_6"><title>Matrigel invasion assay</title><p>Invasion assays were performed in triplicate in six-well trans-well units with 8-&#x003bc;m filters coated with Matrigel (BD Biosciences) at 1:6 dilution. Each well was loaded with ~2 &#x000d7; 10<sup>6</sup> cells. After incubation for 36 hr, cells passing through the filters into bottom wells were fixed with formalin and stained with crystal violet (Sigma). Cell numbers in 10 randomly selected fields (&#x000d7;200) from each well were counted.</p></sec><sec id="s4_7"><title>Luciferase assay</title><p>WT and mutant <italic>MMP-7</italic> luciferase reporters constructed using the pBV-Luc vector were previously described [<xref rid="R12" ref-type="bibr">12</xref>]. For reporter assays, A549 and H1299 cells were co-transfected with fibulin-5 and the transfection control &#x003b2;-galactosidase reporter pCMV&#x003b2; (Promega), along with the TCF-4 reporter plasmid pTOPFlash or the control inactive reporter pFOPFlash, and WT or mutant <italic>MMP-7</italic> reporter. In some experiments, cells were transfected with mutant fibulin-5 with deletion of its RGD motif (&#x00394;RGD). After transfection, collection of cell lysates and measurement of luciferase activities were done as described [<xref rid="R12" ref-type="bibr">12</xref>]. All reporter experiments were performed in triplicate and repeated three times.</p></sec><sec id="s4_8"><title>Analysis of &#x003b2;-catenin nuclear localization</title><p>Nuclear &#x003b2;-catenin in H1299 and A549 cells was analyzed by western blotting of &#x003b2;-catenin in nuclear fractions isolated from transfected cells using the NE-PER nuclear/cytoplasmic extraction kit (ThermoFisher) according to the manufacturer's instructions. Nuclear &#x003b2;-catenin in SW480 colorectal cancer cells and H1752 lung cancer cells were analyzed using immunofluorescence as previously described [<xref rid="R10" ref-type="bibr">10</xref>]. Mounted slides were subjected to microscopic analysis under a Nikon fluorescence microscope (TS800) equipped with a SPOT camera and imaging software.</p></sec><sec id="s4_9"><title>Animal experiments</title><p>All animal experiments were approved by the Institutional Animal Care and Use Committees at the University of Pittsburgh and Tianjin Medical University. Female 5- to 6-week-old BALB/c nude mice (Charles River, Wilmington, MA or Military Academy of Medical Sciences Laboratory Animal Center, Beijing, China) were housed in a sterile environment with microisolator cages and allowed access to water and chow <italic>ad libitum</italic>. To analyze tumor growth, mice were injected subcutaneously in both flanks with parental and fibulin-5-expressing H1299 cells (5 &#x000d7; 10<sup>6</sup> cells/injection). Tumor volumes were calculated according to the formula 0.5 &#x000d7; length &#x000d7; width<sup>2</sup>. To analyze tumor metastasis, stable H460 and H1752 cells expressing lenti-viral <italic>&#x003b2;-catenin</italic>, <italic>GSK3&#x003b2;</italic>, or control scrambled shRNA were injected intravenously (i.v.) by tail vein into BALB/c nude mice. For each injection, 1 &#x000d7; 10<sup>6</sup> cells suspended in 200 &#x003bc;l PBS were used. Following sacrifice of mice at 6 weeks after injection, lung metastasis nodules were analyzed as previously described [<xref rid="R11" ref-type="bibr">11</xref>]. Tumors were dissected and fixed in 10% formalin and embedded in paraffin. Immunostaining was performed using antibodies for V5 (Invitrogen), p-ERK (Thr202/Tyr204; Cell Signaling Technology), &#x003b2;-catenin (BD Biosciences), c-Myc (9E10; Santa Cruz Biotechnology), and MMP-7 (EMD Millipore) [<xref rid="R11" ref-type="bibr">11</xref>]. Tissues from analysis of parental and fibulin-5-expressing H460 tumor metastasis were previously described [<xref rid="R11" ref-type="bibr">11</xref>].</p></sec><sec id="s4_10"><title>Statistical analysis</title><p>Statistical analyses were performed using GraphPad Prism V software. <italic>P</italic> values &#x0003c; 0.05 were considered to be statistically significant. Means + one standard deviation were displayed in the figures.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY FIGURES AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-06-15022-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e1405" position="anchor"/></supplementary-material></sec></body><back><ack><p>The authors would like to thank our lab members for critical reading. This work is supported by the Ministry of Science and Technology of China (2014ZX09101005-004 and 2009CB918903 to Z.Y.), grants from Tianjin Municipal Science and Technology Commission (14JCQNJC12100 to X.C.) and Tianjin Municipal Education Commission (2012ZD01 to X.C.), U.S. National Institute of Health grants (CA106348, CA121105, and CA172136 to L.Z.; CA129829 and U01DK085570 to J.Y.) and American Cancer Society grants (RSG-07-156-01-CNE to L.Z.; RGS-10-124-01-CCE to J.Y.). This project used the University of Pittsburgh Cancer Institute shared facilities that were supported in part by award P30CA047904.</p></ack><fn-group><fn fn-type="conflict"><p><bold>CONFLICTS OF INTEREST</bold></p><p>None declared.</p></fn></fn-group><glossary><def-list><title>Abbreviations</title><def-item><term>DAPI</term><def><p>4&#x02032; 6-Diamidino-2-phenylindole</p></def></def-item><def-item><term>ECM</term><def><p>extracellular matrix</p></def></def-item><def-item><term>EMT</term><def><p>epithelial-mesenchymal transition</p></def></def-item><def-item><term>ERK</term><def><p>extracellular signal-regulated kinase</p></def></def-item><def-item><term>FAK</term><def><p>focal adhesion kinase</p></def></def-item><def-item><term>FP</term><def><p>first progression</p></def></def-item><def-item><term>GSK3&#x003b2;</term><def><p>glycogen synthase kinase 3&#x003b2;</p></def></def-item><def-item><term>GAPDH</term><def><p>glyceraldehyde-3-phosphate dehydrogenase</p></def></def-item><def-item><term>IP</term><def><p>immunoprecipitation</p></def></def-item><def-item><term>MMP</term><def><p>matrix metalloproteinase</p></def></def-item><def-item><term>NSCLC</term><def><p>non-small cell lung cancer</p></def></def-item><def-item><term>OS</term><def><p>overall survival</p></def></def-item><def-item><term>PPS</term><def><p>post-progression survival</p></def></def-item><def-item><term>RGD</term><def><p>Arg-Gly-Asp</p></def></def-item><def-item><term>RT-PCR</term><def><p>reverse transcriptase-polymerase chain reaction</p></def></def-item><def-item><term>shRNA</term><def><p>short hairpin RNA</p></def></def-item><def-item><term>siRNA</term><def><p>small interfering RNA</p></def></def-item><def-item><term>TCF-4</term><def><p>T-cell factor 4</p></def></def-item><def-item><term>TBE</term><def><p>T-cell factor 4 binding element</p></def></def-item><def-item><term>TCGA</term><def><p>The Cancer Genome Atlas</p></def></def-item><def-item><term>TIMP</term><def><p>tissue inhibitor of metalloproteinase</p></def></def-item><def-item><term>WT</term><def><p>wild-type</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics</article-title><source>CA Cancer J Clin</source><year>2014</year><volume>64</volume><fpage>9</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">24399786</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DX</given-names></name><name><surname>Bos</surname><given-names>PD</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>Metastasis: from dissemination to organ-specific colonization</article-title><source>Nat Rev Cancer</source><year>2009</year><volume>9</volume><fpage>274</fpage><lpage>284</lpage><pub-id pub-id-type="pmid">19308067</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Argraves</surname><given-names>WS</given-names></name><name><surname>Greene</surname><given-names>LM</given-names></name><name><surname>Cooley</surname><given-names>MA</given-names></name><name><surname>Gallagher</surname><given-names>WM</given-names></name></person-group><article-title>Fibulins: physiological and disease perspectives</article-title><source>EMBO Rep</source><year>2003</year><volume>4</volume><fpage>1127</fpage><lpage>1131</lpage><pub-id pub-id-type="pmid">14647206</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>WM</given-names></name><name><surname>Currid</surname><given-names>CA</given-names></name><name><surname>Whelan</surname><given-names>LC</given-names></name></person-group><article-title>Fibulins and cancer: friend or foe?</article-title><source>Trends Mol Med</source><year>2005</year><volume>11</volume><fpage>336</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">15961345</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obaya</surname><given-names>AJ</given-names></name><name><surname>Rua</surname><given-names>S</given-names></name><name><surname>Moncada-Pazos</surname><given-names>A</given-names></name><name><surname>Cal</surname><given-names>S</given-names></name></person-group><article-title>The dual role of fibulins in tumorigenesis</article-title><source>Cancer Lett</source><year>2012</year><volume>325</volume><fpage>132</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">22781395</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albig</surname><given-names>AR</given-names></name><name><surname>Schiemann</surname><given-names>WP</given-names></name></person-group><article-title>Fibulin-5 function during tumorigenesis</article-title><source>Future Oncol</source><year>2005</year><volume>1</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">16555973</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>H</given-names></name><name><surname>Schluterman</surname><given-names>MK</given-names></name><name><surname>Brekken</surname><given-names>RA</given-names></name></person-group><article-title>Fibulin-5, an integrin-binding matricellular protein: its function in development and disease</article-title><source>Journal of cell communication and signaling</source><year>2009</year><volume>3</volume><fpage>337</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">19798595</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Lozano</surname><given-names>PR</given-names></name><name><surname>Ikeda</surname><given-names>Y</given-names></name><name><surname>Iwanaga</surname><given-names>Y</given-names></name><name><surname>Hinek</surname><given-names>A</given-names></name><name><surname>Minamisawa</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>CF</given-names></name><name><surname>Kobuke</surname><given-names>K</given-names></name><name><surname>Dalton</surname><given-names>N</given-names></name><name><surname>Takada</surname><given-names>Y</given-names></name><name><surname>Tashiro</surname><given-names>K</given-names></name><name><surname>Ross</surname><given-names>J</given-names><suffix>Jr</suffix></name><name><surname>Honjo</surname><given-names>T</given-names></name><name><surname>Chien</surname><given-names>KR</given-names></name></person-group><article-title>Fibulin-5/DANCE is essential for elastogenesis <italic>in vivo</italic></article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="pmid">11805835</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desgrosellier</surname><given-names>JS</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><article-title>Integrins in cancer: biological implications and therapeutic opportunities</article-title><source>Nat Rev Cancer</source><year>2010</year><volume>10</volume><fpage>9</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20029421</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Dacic</surname><given-names>S</given-names></name><name><surname>Landreneau</surname><given-names>RJ</given-names></name><name><surname>Siegfried</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>84</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">18048388</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>W</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Landreneau</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name><name><surname>Siegfried</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Fibulin-5 suppresses lung cancer invasion by inhibiting matrix metalloproteinase-7 expression</article-title><source>Cancer Res</source><year>2009</year><volume>69</volume><fpage>6339</fpage><lpage>6346</lpage><pub-id pub-id-type="pmid">19584278</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Meng</surname><given-names>J</given-names></name><name><surname>Yue</surname><given-names>W</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Fibulin-3 suppresses Wnt/beta-catenin signaling and lung cancer invasion</article-title><source>Carcinogenesis</source><year>2014</year><volume>35</volume><fpage>1707</fpage><lpage>1716</lpage><pub-id pub-id-type="pmid">24480807</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinckerhoff</surname><given-names>CE</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>Matrix metalloproteinases: a tail of a frog that became a prince</article-title><source>Nat Rev Mol Cell Biol</source><year>2002</year><volume>3</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">11994741</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Cancer genes and the pathways they control</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><fpage>789</fpage><lpage>799</lpage><pub-id pub-id-type="pmid">15286780</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><article-title>Wnt/beta-catenin signaling in development and disease</article-title><source>Cell</source><year>2006</year><volume>127</volume><fpage>469</fpage><lpage>480</lpage><pub-id pub-id-type="pmid">17081971</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winn</surname><given-names>RA</given-names></name><name><surname>Bremnes</surname><given-names>RM</given-names></name><name><surname>Bemis</surname><given-names>L</given-names></name><name><surname>Franklin</surname><given-names>WA</given-names></name><name><surname>Miller</surname><given-names>YE</given-names></name><name><surname>Cool</surname><given-names>C</given-names></name><name><surname>Heasley</surname><given-names>LE</given-names></name></person-group><article-title>gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth</article-title><source>Oncogene</source><year>2002</year><volume>21</volume><fpage>7497</fpage><lpage>7506</lpage><pub-id pub-id-type="pmid">12386812</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>JH</given-names></name><name><surname>Park</surname><given-names>JW</given-names></name><name><surname>Chun</surname><given-names>YS</given-names></name></person-group><article-title>Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation</article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>10677</fpage><lpage>10682</lpage><pub-id pub-id-type="pmid">17108104</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Uematsu</surname><given-names>K</given-names></name><name><surname>Mazieres</surname><given-names>J</given-names></name><name><surname>Mikami</surname><given-names>I</given-names></name><name><surname>Reguart</surname><given-names>N</given-names></name><name><surname>Moody</surname><given-names>TW</given-names></name><name><surname>Kitajewski</surname><given-names>J</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name><name><surname>Jablons</surname><given-names>DM</given-names></name></person-group><article-title>Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells</article-title><source>Oncogene</source><year>2004</year><volume>23</volume><fpage>6170</fpage><lpage>6174</lpage><pub-id pub-id-type="pmid">15208662</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>DX</given-names></name><name><surname>Chiang</surname><given-names>AC</given-names></name><name><surname>Zhang</surname><given-names>XH</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Gerald</surname><given-names>WL</given-names></name><name><surname>Massague</surname><given-names>J</given-names></name></person-group><article-title>WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis</article-title><source>Cell</source><year>2009</year><volume>138</volume><fpage>51</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">19576624</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Wnt signaling pathway: implications for therapy in lung cancer and bone metastasis</article-title><source>Cancer Lett</source><year>2014</year><volume>353</volume><fpage>8</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">25042867</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crawford</surname><given-names>HC</given-names></name><name><surname>Fingleton</surname><given-names>BM</given-names></name><name><surname>Rudolph-Owen</surname><given-names>LA</given-names></name><name><surname>Goss</surname><given-names>KJ</given-names></name><name><surname>Rubinfeld</surname><given-names>B</given-names></name><name><surname>Polakis</surname><given-names>P</given-names></name><name><surname>Matrisian</surname><given-names>LM</given-names></name></person-group><article-title>The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors</article-title><source>Oncogene</source><year>1999</year><volume>18</volume><fpage>2883</fpage><lpage>2891</lpage><pub-id pub-id-type="pmid">10362259</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>TC</given-names></name><name><surname>Sparks</surname><given-names>AB</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Hermeking</surname><given-names>H</given-names></name><name><surname>Zawel</surname><given-names>L</given-names></name><name><surname>da Costa</surname><given-names>LT</given-names></name><name><surname>Morin</surname><given-names>PJ</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name></person-group><article-title>Identification of c-MYC as a target of the APC pathway</article-title><source>Science</source><year>1998</year><volume>281</volume><fpage>1509</fpage><lpage>1512</lpage><pub-id pub-id-type="pmid">9727977</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tetsu</surname><given-names>O</given-names></name><name><surname>McCormick</surname><given-names>F</given-names></name></person-group><article-title>Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells</article-title><source>Nature</source><year>1999</year><volume>398</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">10201372</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Q</given-names></name><name><surname>Xia</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>JC</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>DF</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Bartholomeusz</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Bargou</surname><given-names>RC</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Tsai</surname><given-names>CH</given-names></name><name><surname>Hung</surname><given-names>MC</given-names></name></person-group><article-title>Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin</article-title><source>Mol Cell</source><year>2005</year><volume>19</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">16039586</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cline</surname><given-names>MS</given-names></name><name><surname>Craft</surname><given-names>B</given-names></name><name><surname>Swatloski</surname><given-names>T</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name></person-group><article-title>Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser</article-title><source>Scientific reports</source><year>2013</year><volume>3</volume><fpage>2652</fpage><pub-id pub-id-type="pmid">24084870</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gyorffy</surname><given-names>B</given-names></name><name><surname>Surowiak</surname><given-names>P</given-names></name><name><surname>Budczies</surname><given-names>J</given-names></name><name><surname>Lanczky</surname><given-names>A</given-names></name></person-group><article-title>Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e82241</fpage><pub-id pub-id-type="pmid">24367507</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yue</surname><given-names>W</given-names></name><name><surname>Dacic</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Landreneau</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Siegfried</surname><given-names>JM</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Frequent inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter hypermethylation</article-title><source>Clin Cancer Res</source><year>2007</year><volume>13</volume><fpage>4336</fpage><lpage>4344</lpage><pub-id pub-id-type="pmid">17671114</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Ming</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Van Houten</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>8107</fpage><lpage>8122</lpage><pub-id pub-id-type="pmid">25237903</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Safranek</surname><given-names>J</given-names></name><name><surname>Holubec</surname><given-names>L</given-names><suffix>Jr</suffix></name><name><surname>Topolcan</surname><given-names>O</given-names></name><name><surname>Pesta</surname><given-names>M</given-names></name><name><surname>Klecka</surname><given-names>J</given-names></name><name><surname>Vodicka</surname><given-names>J</given-names></name><name><surname>Finek</surname><given-names>J</given-names></name><name><surname>Kormunda</surname><given-names>S</given-names></name><name><surname>Pesek</surname><given-names>M</given-names></name></person-group><article-title>Expression of mRNA MMP-7 and mRNA TIMP-1 in non-small cell lung cancer</article-title><source>Anticancer Res</source><year>2007</year><volume>27</volume><fpage>2953</fpage><lpage>2956</lpage><pub-id pub-id-type="pmid">17695477</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>TS</given-names></name><name><surname>Chiou</surname><given-names>SH</given-names></name><name><surname>Wang</surname><given-names>LS</given-names></name><name><surname>Huang</surname><given-names>HH</given-names></name><name><surname>Chiang</surname><given-names>SF</given-names></name><name><surname>Shih</surname><given-names>AY</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Hsu</surname><given-names>CP</given-names></name><name><surname>Hsu</surname><given-names>NY</given-names></name><name><surname>Chou</surname><given-names>MC</given-names></name><name><surname>Kuo</surname><given-names>SJ</given-names></name><name><surname>Chow</surname><given-names>KC</given-names></name></person-group><article-title>Expression spectra of matrix metalloproteinases in metastatic non-small cell lung cancer</article-title><source>Oncol Rep</source><year>2004</year><volume>12</volume><fpage>717</fpage><lpage>723</lpage><pub-id pub-id-type="pmid">15375490</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albig</surname><given-names>AR</given-names></name><name><surname>Neil</surname><given-names>JR</given-names></name><name><surname>Schiemann</surname><given-names>WP</given-names></name></person-group><article-title>Fibulins 3 and 5 antagonize tumor angiogenesis <italic>in vivo</italic></article-title><source>Cancer Res</source><year>2006</year><volume>66</volume><fpage>2621</fpage><lpage>2629</lpage><pub-id pub-id-type="pmid">16510581</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>HD</given-names></name><name><surname>Ralfkjaer</surname><given-names>U</given-names></name><name><surname>Cremers</surname><given-names>N</given-names></name><name><surname>Frankel</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>RT</given-names></name><name><surname>Klingelhofer</surname><given-names>J</given-names></name><name><surname>Yanagisawa</surname><given-names>H</given-names></name><name><surname>Grigorian</surname><given-names>M</given-names></name><name><surname>Guldberg</surname><given-names>P</given-names></name><name><surname>Sleeman</surname><given-names>J</given-names></name><name><surname>Lukanidin</surname><given-names>E</given-names></name><name><surname>Ambartsumian</surname><given-names>N</given-names></name></person-group><article-title>Role of fibulin-5 in metastatic organ colonization</article-title><source>Mol Cancer Res</source><year>2011</year><volume>9</volume><fpage>553</fpage><lpage>563</lpage><pub-id pub-id-type="pmid">21454378</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>CF</given-names></name><name><surname>Shiu</surname><given-names>LY</given-names></name><name><surname>Su</surname><given-names>LJ</given-names></name><name><surname>Yu-Fang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>WS</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Chiu</surname><given-names>TJ</given-names></name><name><surname>Huang</surname><given-names>CC</given-names></name><name><surname>Zhen</surname><given-names>YY</given-names></name><name><surname>Tsai</surname><given-names>HT</given-names></name><name><surname>Fang</surname><given-names>FM</given-names></name><name><surname>Huang</surname><given-names>TL</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name></person-group><article-title>Oncogenic fibulin-5 promotes nasopharyngeal carcinoma cell metastasis through the FLJ10540/AKT pathway and correlates with poor prognosis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e84218</fpage><pub-id pub-id-type="pmid">24386352</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YH</given-names></name><name><surname>Albig</surname><given-names>AR</given-names></name><name><surname>Regner</surname><given-names>M</given-names></name><name><surname>Schiemann</surname><given-names>BJ</given-names></name><name><surname>Schiemann</surname><given-names>WP</given-names></name></person-group><article-title>Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism</article-title><source>Carcinogenesis</source><year>2008</year><volume>29</volume><fpage>2243</fpage><lpage>2251</lpage><pub-id pub-id-type="pmid">18713838</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>PP</given-names></name><name><surname>Goldstein</surname><given-names>RH</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Rishikof</surname><given-names>DC</given-names></name><name><surname>Jean</surname><given-names>JC</given-names></name><name><surname>Joyce-Brady</surname><given-names>M</given-names></name></person-group><article-title>Coordinate expression of fibulin-5/DANCE and elastin during lung injury repair</article-title><source>Am J Physiol Lung Cell Mol Physiol</source><year>2003</year><volume>285</volume><fpage>L1147</fpage><lpage>1152</lpage><pub-id pub-id-type="pmid">12909585</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merklinger</surname><given-names>SL</given-names></name><name><surname>Wagner</surname><given-names>RA</given-names></name><name><surname>Spiekerkoetter</surname><given-names>E</given-names></name><name><surname>Hinek</surname><given-names>A</given-names></name><name><surname>Knutsen</surname><given-names>RH</given-names></name><name><surname>Kabir</surname><given-names>MG</given-names></name><name><surname>Desai</surname><given-names>K</given-names></name><name><surname>Hacker</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Cann</surname><given-names>GM</given-names></name><name><surname>Ambartsumian</surname><given-names>NS</given-names></name><name><surname>Lukanidin</surname><given-names>E</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Husain</surname><given-names>M</given-names></name><name><surname>Mecham</surname><given-names>RP</given-names></name><name><surname>Starcher</surname><given-names>B</given-names></name><name><surname>Yanagisawa</surname><given-names>H</given-names></name><name><surname>Rabinovitch</surname><given-names>M</given-names></name></person-group><article-title>Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension</article-title><source>Circ Res</source><year>2005</year><volume>97</volume><fpage>596</fpage><lpage>604</lpage><pub-id pub-id-type="pmid">16109920</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagisawa</surname><given-names>H</given-names></name><name><surname>Davis</surname><given-names>EC</given-names></name><name><surname>Starcher</surname><given-names>BC</given-names></name><name><surname>Ouchi</surname><given-names>T</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><name><surname>Olson</surname><given-names>EN</given-names></name></person-group><article-title>Fibulin-5 is an elastin-binding protein essential for elastic fibre development <italic>in vivo</italic></article-title><source>Nature</source><year>2002</year><volume>415</volume><fpage>168</fpage><lpage>171</lpage><pub-id pub-id-type="pmid">11805834</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Scoyk</surname><given-names>M</given-names></name><name><surname>Randall</surname><given-names>J</given-names></name><name><surname>Sergew</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>LM</given-names></name><name><surname>Tennis</surname><given-names>M</given-names></name><name><surname>Winn</surname><given-names>RA</given-names></name></person-group><article-title>Wnt signaling pathway and lung disease</article-title><source>Translational research : the journal of laboratory and clinical medicine</source><year>2008</year><volume>151</volume><fpage>175</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">18355764</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minna</surname><given-names>JD</given-names></name><name><surname>Roth</surname><given-names>JA</given-names></name><name><surname>Gazdar</surname><given-names>AF</given-names></name></person-group><article-title>Focus on lung cancer</article-title><source>Cancer Cell</source><year>2002</year><volume>1</volume><fpage>49</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">12086887</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rapp</surname><given-names>UR</given-names></name><name><surname>Korn</surname><given-names>C</given-names></name><name><surname>Ceteci</surname><given-names>F</given-names></name><name><surname>Karreman</surname><given-names>C</given-names></name><name><surname>Luetkenhaus</surname><given-names>K</given-names></name><name><surname>Serafin</surname><given-names>V</given-names></name><name><surname>Zanucco</surname><given-names>E</given-names></name><name><surname>Castro</surname><given-names>I</given-names></name><name><surname>Potapenko</surname><given-names>T</given-names></name></person-group><article-title>MYC is a metastasis gene for non-small-cell lung cancer</article-title><source>PLoS One</source><year>2009</year><volume>4</volume><fpage>e6029</fpage><pub-id pub-id-type="pmid">19551151</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villar</surname><given-names>J</given-names></name><name><surname>Cabrera</surname><given-names>NE</given-names></name><name><surname>Valladares</surname><given-names>F</given-names></name><name><surname>Casula</surname><given-names>M</given-names></name><name><surname>Flores</surname><given-names>C</given-names></name><name><surname>Blanch</surname><given-names>L</given-names></name><name><surname>Quilez</surname><given-names>ME</given-names></name><name><surname>Santana-Rodriguez</surname><given-names>N</given-names></name><name><surname>Kacmarek</surname><given-names>RM</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name></person-group><article-title>Activation of the Wnt/beta-catenin signaling pathway by mechanical ventilation is associated with ventilator-induced pulmonary fibrosis in healthy lungs</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e23914</fpage><pub-id pub-id-type="pmid">21935365</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hood</surname><given-names>JD</given-names></name><name><surname>Cheresh</surname><given-names>DA</given-names></name></person-group><article-title>Role of integrins in cell invasion and migration</article-title><source>Nat Rev Cancer</source><year>2002</year><volume>2</volume><fpage>91</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">12635172</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez</surname><given-names>DM</given-names></name><name><surname>Medici</surname><given-names>D</given-names></name></person-group><article-title>Signaling mechanisms of the epithelial-mesenchymal transition</article-title><source>Science signaling</source><year>2014</year><volume>7</volume><fpage>re8</fpage><pub-id pub-id-type="pmid">25249658</pub-id></element-citation></ref></ref-list></back></article>